Shares of AbCellera Biologics slid 7% to $10.53 on August 24 as investors continued digesting a large stock offering that flooded the market with new shares at a steep discount. The sell-off raises a pointed question: did the company sell its stock too cheaply, or is this the cost of betting big on a promising hot-flash drug?
The Company Sold New Stock at a Big Discount, and Existing Shareholders Are Paying for It
AbCellera priced 17.4 million new common shares at $9.75 apiece, along with pre-funded warrants covering an additional 3.1 million shares. That $9.75 price was roughly 19% below the stock's August 19 close of $12.01 — a level reached after a clinical-trial-fueled rally. The company's net tangible book value stood at just $2.65 per share as of June 30, meaning new investors face immediate dilution of $6.67 per share.
With roughly 305 million shares already outstanding , the offering adds approximately 6.7% more stock to the float, spreading future profits — whenever they arrive — across more owners.
A Hot-Flash Drug Triggered the Rally That Made This Offering Possible
AbCellera's stock surged as much as 41% on August 10 after it reported its non-hormonal hot-flash treatment was effective in a mid-stage trial , briefly pushing its market value near $3 billion. The drug showed significant reductions in symptom frequency and severity, with high rates of complete resolution. Management appears to have seized the momentum to raise capital — a common biotech playbook, but one that inevitably caps the rally.
The Cash Buys Runway, but the Losses Are Still Wide
Net proceeds of approximately $187 million
will fund continued development of AbCellera's lead program and general corporate purposes.
In the trailing twelve months, AbCellera generated just $79 million in revenue against $144 million in losses.
Recent partnerships with Jazz Pharmaceuticals and Vertex have brought in over $110 million in upfront cash , but the company's burn rate means this offering buys time, not profitability.
Analysts Still See Upside — If the Drug Delivers
JonesResearch raised its price target to $25 with a Buy rating , and the most recent consensus analyst rating carries a $30 target — nearly triple today's price. But 14.7% of outstanding shares are sold short , a sign that a significant share of Wall Street is betting the dilution and cash burn will outweigh the clinical promise. The next twelve months — as the hot-flash drug advances — will determine which side is right.